How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?

Abstract

Solid pseudopapillary neoplasm of the pancreas is a rare and distinct pancreatic tumor that occurs almost exclusively in young women. It is typically viewed as having low malignant potential but may sometimes show aggressive behavior, such as liver metastases. Management of SPN with involvement of the liver presents challenges because it involves both surgical resection and systemic and targeted interventions in a multidisciplinary approach. This review discusses the pathophysiology, diagnostic modalities, treatment options, and long-term outcomes associated with SPN and its metastatic manifestations. Advances in molecular profiling and novel therapeutic strategies hold promise for improved patient outcomes. By addressing current challenges and emerging trends, this article provides a comprehensive understanding of the optimal management strategies for SPN with hepatic metastases.

Introduction

The solid pseudopapillary neoplasm of the pancreas is a rare entity, with an incidence of about 1 to 2% of the cases of pancreatic tumors. Solid pseudopapillary neoplasm, first described by Franz in 1959, has a distinct histopathological appearance characterized by both solid and cystic components. Although most cases have an indolent course and favorable prognosis after surgical resection, some cases show aggressive features, such as local invasion and distant metastasis, which typically target the liver. The presence of hepatic metastases poses significant clinical dilemmas, influencing both therapeutic strategies and prognostic outcomes.

The present review covers epidemiology, clinical presentation, radiological and histopathological features, and the current treatment approach to SPN with hepatic metastases. Further, challenges in management and emerging therapeutic modalities that can enhance disease control and survival are discussed.

Epidemiology and Clinical Presentation

SPN mainly occurs in females in the second and third decades of life, though cases are also found in all age groups and both sexes. Due to the slow growth pattern of this tumor, it usually happens with an asymptomatic presentation, with incidental imaging carried out for unrelated conditions. When patients do present with symptoms, they are usually nonspecific and can include such things as abdominal pain, palpable mass, nausea and vomiting, and jaundice when there is obstruction of the biliary tree.

The metastatic potential of SPN is relatively low, with distant spread rates reported between 10% and 15%. The liver is the most common site of metastasis, followed by the peritoneum, lymph nodes, and rarely other distant organs. Identifying hepatic involvement is critical for treatment planning because complete resection remains the cornerstone of curative therapy.

Diagnosis and Imaging Modalities

Accurate diagnosis of SPN with hepatic metastases relies on a combination of imaging studies, histopathological evaluation, and, in some cases, molecular analysis. The key imaging modalities include:

1. Computed Tomography (CT) Scan – A contrast-enhanced CT scan typically reveals a well-encapsulated pancreatic mass with heterogeneous enhancement due to its solid and cystic components. Hepatic metastases may present as low-attenuation lesions with similar characteristics.

2. Magnetic Resonance Imaging (MRI) – MRI provides superior soft tissue contrast, allowing better differentiation of SPN from other pancreatic neoplasms. SPN lesions often demonstrate high T2 signal intensity with peripheral enhancement.

3. Endoscopic Ultrasound (EUS) with Fine-Needle Aspiration (FNA) – EUS-guided FNA enables cytological and immunohistochemical analysis, confirming the diagnosis through characteristic beta-catenin and vimentin expression.

4. Positron Emission Tomography (PET-CT) – While not routinely used, PET-CT may be beneficial in detecting occult metastatic disease, particularly in patients with recurrent or high-risk SPN.

Histopathology and Molecular Features

Histologically, SPN is characterized by a combination of solid, cystic, and pseudopapillary patterns with uniform, monomorphic cells. Immunohistochemistry is essential for diagnosis, with tumor cells typically expressing:

• Beta-catenin (nuclear and cytoplasmic staining)

• CD10

• Vimentin

• Progesterone receptor (PR)

• Negative staining for chromogranin and synaptophysin (helping distinguish SPN from neuroendocrine tumors)

Recent advances in molecular profiling have identified mutations in the CTNNB1 gene encoding beta-catenin as a hallmark genetic alteration in SPN. Understanding these molecular pathways may pave the way for targeted therapies in cases with metastatic or unresectable disease.

Treatment Strategies

1. Surgical Resection

   • Complete surgical excision remains the mainstay of treatment for both localized and metastatic SPN.

   • Pancreaticoduodenectomy or distal pancreatectomy is performed depending on the tumor location.

   • In cases with resectable hepatic metastases, synchronous or staged hepatectomy offers a potential cure.

2. Minimally Invasive Approaches

   • Laparoscopic and robotic-assisted pancreatic surgery is gaining traction, offering reduced morbidity and shorter hospital stays.

   • The feasibility of laparoscopic hepatectomy for limited hepatic metastases is under investigation.

3. Liver-Directed Therapies

   • For patients with unresectable hepatic metastases, liver-directed therapies such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and selective internal radiation therapy (SIRT) can be considered for disease control.

4. Systemic Therapy

   • While SPN is generally chemoresistant, selected cases with aggressive behavior may benefit from systemic chemotherapy or molecularly targeted agents.

   • Clinical trials investigating novel agents targeting beta-catenin and Wnt signaling pathways are ongoing.

Prognosis and Long-Term Outcomes

The overall prognosis for SPN remains favorable, with 5-year survival rates exceeding 95% for localized disease following complete resection. Even in metastatic cases, long-term survival is possible with aggressive surgical intervention. Recurrence rates are low, but close postoperative surveillance is recommended.

Challenges and Future Directions

Despite its relatively indolent nature, SPN poses several challenges, particularly in the metastatic setting. Key areas requiring further research include:

• Identification of high-risk molecular subtypes predictive of aggressive behavior.

• Optimization of systemic therapies for unresectable or recurrent SPN.

• Standardization of surveillance protocols to detect recurrence early.

Conclusion

Pancreatic solid pseudopapillary neoplasm with metastases to the liver presents unique diagnostic and therapeutical challenges. Though surgical resection remains the mainstay curative intervention, prospects are good for enhanced outcomes with unresectable cases through the use of liver-directed therapies as well as emerging systemic treatments. Further studies on the molecular underpinnings of SPN will be important for working toward targeted therapeutic approaches and refining treatment algorithms. A multidisciplinary approach remains pivotal in optimizing patient care and ensuring long-term disease control.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors